GSK wins FDA approval for hepatitis B drug, expands functional cure rates

GSK received FDA approval for a hepatitis B treatment that achieved functional cures in a significantly larger proportion of patients than prior therapies. The approval marks a notable advance in hepatitis B management, though long-term durability and real-world effectiveness remain to be seen. This could shift treatment paradigms and impact GSK's commercial prospects in the infectious disease market.